Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

1230 - Phase II study of atorvastatin in combination with radiotherapy and temozolomide In patients with glioblastoma (ART): interim analysis report


09 Oct 2016


Poster display


Abdullah Altwairgi


Annals of Oncology (2016) 27 (6): 103-113. 10.1093/annonc/mdw367


A.K. Altwairgi1, W. Alghareeb1, F. Alnajjar1, E. Alsaeed1, A. Balbaid1, H. Alhussain1, S. Aldanan1, Y. Orz2, A. Lari2, A. Alsharm1

Author affiliations

  • 1 Comprehensive Cancer Center, King Fahad Medical City, 11525 - Riyadh/SA
  • 2 National Neuroscience Institute, King Fahad Medical City, 11525 - Riyadh/SA


Abstract 1230


Glioblastoma (GBM) is the commonest primary brain tumor in adult and it carries the worst prognosis. Atorvastatin is an inhibitor of HMG-CoA reductase, a rate limiting enzyme in the mevalonate pathway. Preclinical studies demonstrate encouraging anticancer activity of statins.


In this open-label, prospective, single-arm, phase II study, eligible patients received oral Atorvastatin (40 mg/d for 3 weeks and 80 mg/d thereafter) in combination with standard therapy comprising radiotherapy (60 Gy/30 fractions) and TMZ (75 mg/m2/d) in the 6-wk concurrent phase, then with TMZ (150-200 mg/m2/d on days 1-5 for 6 cycles). The primary endpoint is progression free survival (PFS) at 6 months. A minimum of 80% power required at least 32 eligible patients with planned interim analysis after the first 15 evaluable patients.


From January 2014, 20 of 32 planned patients have received therapy and the first 15 evaluable patients were included in this planned interim analysis. Median age was 48 (20-69); 28% were ≥ 60 years of age and 61% were male. 95% of patients underwent resection and 5% had biopsy only. Patients had median and minimum follow-up of 11.6 months and 6 months, respectively. PFS-6 rate was 67% with median PFS of 9.1 months. Median overall survival has not yet been reached to date. Grades 3 and 4 hematological adverse events occurred in 33% of patients. Three patient died due to disease progression.


This is the first clinical trial investigating statins in combination with standard therapy (RT and TMZ) in newly diagnosed GBM patients. Planned interim analysis appears promising and it met criteria for continued accrual.To date, the treatment was safe in this patient population. clinical trial information: NCT02029573

Clinical trial identification


Legal entity responsible for the study

Ministry of Health, Saudi Arabia


King Fahad Medical City


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings